BAT’s US Bio-tech arm, Kentucky BioProcessing (KBP) today announced plans to commence a Phase I first-time-in-human study of its COVID-19 vaccine candidate following approval of its Investigational New Drug application by the U.S. Food and Drug Administration (FDA). Enrollment for the study is expected to begin shortly. Full press release, intended for use by the media only, available at BAT.com.
